SASiavash Atrchian

Siavash Atrchian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Siavash Atrchian has a total of 73 co-authors. Here are the top co-authors by number of shared publications:

  • Angela Lin

    University of British Columbia, 2329 West Mall, Vancouver, BC V6T 1Z4, Canada; BC Cancer - Kelowna, 399 Royal Avenue, Kelowna, BC V1Y 5L3, Canada

    4 shared publications
  • Benjamin Mou

    Division of Radiation Oncology, Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada; Department of Radiation Oncology, BC Cancer Kelowna, Kelowna, British Columbia, Canada

    4 shared publications
  • Mitchell Liu

    Division of Radiation Oncology, Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada; Department of Radiation Oncology, BC Cancer Vancouver, Vancouver, British Columbia, Canada

    4 shared publications
  • Chad Lund

    3 shared publications
  • Fred Hsu

    University of British Columbia, 2329 West Mall, Vancouver, BC V6T 1Z4, Canada; BC Cancer - Abbotsford, 32900 Marshall Road, Abbotsford, BC V2S 0C2, Canada

    3 shared publications
  • Abraham Alexander

    University of British Columbia, 2329 West Mall, Vancouver, BC V6T 1Z4, Canada; BC Cancer - Victoria, 2410 Lee Avenue, Victoria, BC V8R 6V5, Canada

    2 shared publications

Latest Publications

  • Population-based analysis of single-fraction versus multi-fraction stereotactic ablative radiotherapy for early-stage non-small cell lung cancer

    by Karen Anne Aguirre-Meneses, Sarah Baker, Jose Miguel Callueng, Nick Chng, David Petrik, Emma Maria Dunne, Siavash Atrchian, Angela Lin, Allison Ye, Chad Lund, et al.

  • Open Access

    Long-Term Cause-Specific Survival and Late Recurrence in Thymoma: A Provincial Cohort Study

    by Danlin Zeng, Eric Wu, Heather Derocher, Angela Lin, Jodi Siever, Sanjay Rao, Tami Yu-Yu Lin, Daegan Sit, Sonja Murchison, Delia Sauciuc, et al.

    Introduction. Thymoma is a slow-growing mediastinal tumour that can recur more than a decade after resection, and prolonged survival makes competing causes of mortality clinically important. We characterized long-term outcomes in a provincial cohort.Methods. Patients with thymoma diagnosed in British Columbia during 1999–2017 were identified through the provincial cancer registry. Overall survival (OS) was estimated by Kaplan-Meier and cumulative incidences of thymoma-related death, other-cause death, and recurrence by Aalen-Johansen methods. Cause of death was unrecorded in 29 of 79 deaths (36.7%); an observed-rate stochastic imputation model and extreme-bound sensitivity analyses were performed.Results. Of 319 thymoma cases, 238 (74.6%) had records permitting reliable abstraction. Median follow-up was 8.7 years. At 10 years, OS was 72.2% and cause-specific survival was 88.1%, a difference of 15.9 percentage points; cumulative incidences of thymoma-related and other-cause death were 10.9% and 16.9%. Among 145 R0-resected patients, 10-year cumulative incidence of recurrence was 11.9%. Across all 31 recurrences, irrespective of resection margin, 11 (35.5%) occurred after 5 years and 5 (16.1%) after 10 years; median post-recurrence survival was 122.2 months.Conclusions. Missing cause-of-death data introduce uncertainty, but thymoma-related mortality was lower than other-cause mortality. The cause-specific survival–OS gap informs counseling and adjuvant treatment decisions. Recurrence after R0 resection was uncommon; recurrence was often late and post-recurrence survival prolonged. Late recurrence is consistent with National Comprehensive Cancer Network recommendations for CT surveillance through 10 years and supports consideration of longer follow-up for selected patients.

  • Open Access

    Five-year follow-up of the SABR-5 trial: primary toxicity analysis of stereotactic ablative radiotherapy for up to five oligometastases

    by Robert Olson, Mitchell Liu, Alanah Bergman, Benjamin Mou, Hadassah Abraham, Curtis Leclerc, Hannah Carolan, Devin Schellenberg, Will Jiang, Abraham Alexander, et al.


  • Open Access

    Five-Year Follow-Up of the SABR 5 Trial: Primary Toxicity Analysis of Stereotactic Ablative Radiotherapy for Up to Five Oligometastases

    by Robert Anton Olson, Mitchell Liu, Alanah Bergman, Benjamin Mou, Hadassah Abraham, Curtis Leclerc, Hannah Carolan, Devin Schellenberg, Wei Ning (Will) Jiang, Abraham Alexander, et al.

    Background and purposeSABR-5 was a provincially coordinated, single-arm phase II trial of SABR for patients with up to five extracranial metastases across all six BC Cancer centres. The primary objective was to prospectively quantify treatment-related toxicity in a population-based setting. This analysis reports extended follow-up and long-term toxicity outcomes.Materials and methodsAdults with oligometastatic or oligoprogressive disease (≤5 extracranial metastases) were enrolled between 2016 – 2020, when SABR for these indications in BC was available only through this trial. All grade ≥3 events underwent central review by a provincial toxicity committee. Toxicity was evaluated using crude per-patient rates, cumulative incidence methods, annual landmark analyses to year 5, and assessment of toxicity duration. Median follow-up for this update was 54.2 months.ResultsA total of 380 patients were treated (median age 69 years; 32% female). Most patients (91%) had one or two lesions treated. Crude per-patient rates of treatment-related toxicity were 18.9% for grade 2, 5.8% for grade 3, 0.0% for grade 4, and 0.3% for grade 5. There were no additional treatment-related deaths beyond the single previously reported case. The most frequent grade ≥3 toxicities were fracture (2.9%) and pain (1.8%). The cumulative incidence of grade 2 and grade ≥3 toxicity at 5 years was 24% and 7%, respectively. Annual landmark analyses demonstrated that most evaluable patients remained grade 0–1 at each timepoint. Analysis of toxicity duration demonstrated that most grade 3 events resolved within a year (median durations typically <12 months), and persistent long-term toxicity was uncommon and predominantly low-grade.ConclusionSABR delivered within a population-based, quality-assured program is associated with a low incidence of late high-grade toxicity and no new treatment-related deaths. These findings provide durable reassurance regarding the long-term safety of SABR for patients with limited extracranial metastatic disease.

  • Population-Based Outcomes of Single-Fraction Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer

    by J.M. Callueng, S. Baker, N. Chng, J.P. Abrina, D. Hoegler, D. Petrik, E.M. Dunne, I. Mohamed, R. Halperin, S. Atrchian, et al.


  • Effects of Palliative Esophageal External Beam Radiation Therapy in Patients with Stent for Esophageal Cancer: A Retrospective Cohort Study

    by Emily Adams, Héloïse Lavoie-Gagnon, Farhana Islam, Michael Humer, Benjamin Mou, Theodora A. Koulis, David Kim, Siavash Atrchian

    Purpose Self-expandable metallic stents (SEMS) provide immediate but nondurable dysphagia relief in esophageal cancer, while external beam radiotherapy (EBRT) provides slower, more durable dysphagia relief. While the combination of SEMS with EBRT would seem to offer both rapid and durable dysphagia relief in the palliative setting, there remains controversy on its safety and efficacy. We investigated patient outcomes regarding EBRT after SEMS placement in patients with incurable esophageal cancer at a regional Canadian cancer program. Methods We conducted a single-centre retrospective chart review from January 2010 to July 2020 to compare stent-related complications and survival in patients with incurable esophageal cancer treated with SEMS alone or SEMS + EBRT at Kelowna General Hospital. Results 66 patients were included in the SEMS alone group and 26 in the SEMS + EBRT group. Patients treated with SEMS alone showed an average of 3.05 fewer stent-related complications compared to patients who received SEMS + EBRT. The SEMS alone group also had 9.05 greater odds of experiencing higher grade complications compared to the SEMS + EBRT group (p < 0.001). Patients in the SEMS + EBRT group survived significantly longer than those treated with SEMS alone, with a median overall survival of 163.5 days and 65 days, respectively. Conclusions SEMS monotherapy was associated with significantly fewer, yet higher grade stent-related complications compared to palliative EBRT after SEMS placement. SEMS + EBRT treatment was associated with significantly prolonged survival compared to SEMS alone. Prospective studies are needed to confirm these findings.